Bio-diagnostic performances of microRNAs set related to DNA damage response pathway among hepatitis C virus-associated hepatocellular carcinoma patients
Tóm tắt
Up to date, a well-defined microRNAs (miRNAs) profile involved in hepatocellular carcinoma (HCC) pathogenesis remains indecisive. Thus, employing miRNAs for HCC diagnosis is demanded for early therapeutic interventions. We aimed to evaluate the usage of miRNAs set related to the SuperPath: miRNAs involved in DNA damage response pathway as effective biomarkers for HCV-related HCC diagnosis. The study enrolled 97 patients with HCV-related HCC, 84 with hepatitis C virus (HCV), 97 with liver cirrhosis (LC), and 84 healthy individuals. Serum miRNA-23a, miRNA-203, miRNA-100-5p, and miRNA-16 were quantified using qRT-PCR experiments, AFP and routine LFTs were estimated via standard techniques. Pathway enrichment analysis along with the construction of miRNAs regulatory network were performed. With respect to healthy individuals, miRNA-203, miRNA-100-5p, and miRNA-16 were significantly downregulated in HCC, HCV, and LC groups, while miRNA-23a showed significant upregulation (p < 0.001). miRNAs exhibited significant correlations with AFP, ALT, AST, and albumin. Also, elevated levels of miRNA-23a were recognized in patients with multiple focal lesions and/or lesion size > 5 cm. Additionally, the diagnostic performance of miRNA-23a expression level at a selected cut-off value of 3.99 overtakes AFP, while expressions of miR-203, miRNA-100-5p, and miRNA-16 represent poor diagnostic outcomes. Keeping in mind the individual variability and high level of heterogeneity in HCC, our data revealed the diagnostic value of miRNA-23a expression in HCV-related HCC patients. Further extra in silico HCC-specific microRNAs sets are demanded in diagnosis.
Tài liệu tham khảo
Bai X, Liu Z, Shao X, Wang D, Dong E, Wang Y, Li C (2019) The heterogeneity of plasma miRNA profiles in hepatocellular carcinoma patients and the exploration of diagnostic circulating miRNAs for hepatocellular carcinoma. Plos One 14(2):e0211581
Parkin DM, Bray F, Ferlay J, Pisani P (2005) Global cancer statistics, 2002. CA Cancer J Clin 55(2):74–108. https://doi.org/10.3322/canjclin.55.2.74
Li J, Huang Z, Wei L (2016) Bioinformatics analysis of the gene expression profile of hepatocellular carcinoma: preliminary results. Contemp Oncol/Współczesna Onkologia 20(1):20–27
Thorgeirsson SS, Grisham JW (2002) Molecular pathogenesis of human hepatocellular carcinoma. Nat Genet 31(4):339–346
Chen P, Zhao X, Ma L (2013) Downregulation of microRNA-100 correlates with tumor progression and poor prognosis in hepatocellular carcinoma. Mol Cell Biochem 383(1):49–58
Giordano S, Columbano A (2013) MicroRNAs: new tools for diagnosis, prognosis, and therapy in hepatocellular carcinoma? Hepatology 57(2):840–847
Chen XM (2009) MicroRNA signatures in liver diseases. World J Gastroenterol 15(14):1665
Morishita A, Oura K, Tadokoro T, Fujita K, Tani J, Masaki T (2021) MicroRNAs in the pathogenesis of hepatocellular carcinoma: a review. Cancers 13(3):514
Pugh RN, Murray-Lyon IM, Dawson JL, Pietroni MC, Williams R (1973) Transection of the oesophagus for bleeding oesophageal varices. Br J Surg 60(8):646–649. https://doi.org/10.1002/bjs.1800600817
Okuda K, Ohtsuki T, Obata H, Tomimatsu M, Okazaki N, Hasegawa H, Nakajima Y, & Ohnishi K. (1985). Natural history of hepatocellular carcinoma and prognosis in relation to treatment Study of 850 patients. Cancer 56(4):918–928. https://doi.org/10.1002/1097-0142(19850815)56:4<918::aid-cncr2820560437>3.0.co;2-e
Uzuner E, Ulu GT, Gürler SB, Baran Y (2022) The role of MiRNA in cancer: pathogenesis, diagnosis, and treatment. miRNomics. Humana, New York
Kashyap D, Tuli HS, Garg VK, Goel N, Bishayee A (2018) Oncogenic and tumor-suppressive roles of MicroRNAs with special reference to apoptosis: molecular mechanisms and therapeutic potential. Mol Diagnosis Ther 22(2):179–201
Li LM, Hu ZB, Zhou ZX, Chen X, Liu FY, Zhang JF, Shen HB, Zhang CY, Zen K (2010) Serum microRNA profiles serve as novel biomarkers for HBV infection and diagnosis of HBV-positive hepatocarcinoma. Cancer Res 70(23):9798–9807. https://doi.org/10.1158/0008-5472.CAN-10-1001
Kurkewich JL, Hansen J, Klopfenstein N, Zhang H, Wood C, Boucher A, Dahl R (2017) The miR-23a~ 27a–24-2 microRNA cluster buffers transcription and signaling pathways during hematopoiesis. PLoS Genet 13(7):e1006887
Yan Y, Liang Z, Du Q, Yang M, Geller DA (2016) MicroRNA-23a downregulates the expression of interferon regulatory factor-1 in hepatocellular carcinoma cells. Oncol Rep 36(2):633–640
Wang N, Tan HY, Feng YG, Zhang C, Chen F, Feng Y (2018) microRNA-23a in human cancer: its roles, mechanisms and therapeutic relevance. Cancers 11(1):7
Wang B, Hsu SH, Frankel W, Ghoshal K, Jacob ST (2012) Stat3-mediated activation of microRNA-23a suppresses gluconeogenesis in hepatocellular carcinoma by down-regulating glucose-6-phosphatase and peroxisome proliferator-activated receptor gamma, coactivator 1 alpha. Hepatology 56(1):186–197
Chen HY, Han ZB, Fan JW, Xia J, Wu JY, Qiu GQ, Peng ZH (2012) miR-203 expression predicts outcome after liver transplantation for hepatocellular carcinoma in cirrhotic liver. Med Oncol 29(3):1859–1865
Liu Y, Ren F, Rong M, Luo Y, Dang Y, Chen G (2015) Association between underexpression of microrna-203 and clinicopathological significance in hepatocellular carcinoma tissues. Cancer Cell Int 15(1):1–9
Yang CH, Wang Y, Sims M, Cai C, He P, Yue J, Pfeffer LM (2016) MiRNA203 suppresses the expression of protumorigenic STAT1 in glioblastoma to inhibit tumorigenesis. Oncotarget 7(51):84017
Wei W, Wanjun L, Hui S, Dongyue C, Xinjun Y, Jisheng Z (2013) miR-203 inhibits proliferation of HCC cells by targeting survivin. Cell Biochem Function 31(1):82–85
He QL, Qin SY, Tao L, Ning HJ, Jiang HX (2019) Prognostic value and prospective molecular mechanism of miR 100 5p in hepatocellular carcinoma: a comprehensive study based on 1,258 samples. Oncol Lett 18(6):6126–6142
Song SK, Jung WY, Park SK, Chung CW, Park Y (2019) Significantly different expression levels of microRNAs associated with vascular invasion in hepatocellular carcinoma and their prognostic significance after surgical resection. PLoS One 14(9):e0216847
Varnholt H, Drebber U, Schulze F, Wedemeyer I, Schirmacher P, Dienes HP, Odenthal M (2008) MicroRNA gene expression profile of hepatitis C virus–associated hepatocellular carcinoma. Hepatology 47(4):1223–1232
Jin Y, Wong YS, Goh BK, Chan CY, Cheow PC, Chow PK, Lee CG (2019) Circulating microRNAs as potential diagnostic and prognostic biomarkers in hepatocellular carcinoma. Sci Rep 9(1):1–12
Liu Z, Sun Q, Wang X (2017) PLK1, a potential target for cancer therapy. Transl Oncol 10(1):22–32
Li C, Gao Y, Zhang K, Chen J, Han S, Feng B, Chen L (2015) Multiple roles of microRNA-100 in human cancer and its therapeutic potential. Cell Physiol Biochem 37(6):2143–2159
El-Abd NE, Fawzy NA, El-Sheikh SM, Soliman ME (2015) Circulating miRNA-122, miRNA-199a, and miRNA-16 as biomarkers for early detection of hepatocellular carcinoma in Egyptian patients with chronic hepatitis C virus infection. Mol Diagnosis Ther 19(4):213–220
Zhu B, Wei XX, Wang TB, Zhou YC, Liu AM, Zhang GW (2015) Increased miR-16 expression induced by hepatitis C virus infection promotes liver fibrosis through downregulation of hepatocyte growth factor and Smad7. Arch Virol 160(8):2043–2050
Qu KZ, Zhang K, Li H, Afdhal NH, Albitar M (2011) Circulating microRNAs as biomarkers for hepatocellular carcinoma. J Clin Gastroenterol 45(4):355–360
Beltagy DM, Khedr YI, Sakr AHA (2020) Diagnostic and prognostic roles of miRNA and dielectric parameters in HCV Egyptian patients. J Appl Pharm Sci 10(9):115–121
Krekulova L, Oktabec Z, Riley LW (2022) Key role of multidisciplinary collaboration towards global elimination of HCV infection. Int J Environ Res Public Health 19(7):4158
El-Ahwany E, Mourad L, Zoheiry M, Abu-Taleb H, Hassan M, Atta R, Zada S (2019) MicroRNA-122a as a non-invasive biomarker for HCV genotype 4-related hepatocellular carcinoma in Egyptian patients. Arch Med Sci 15(6):1454–1461
He Y, Lu H, Zhang L (2019) Serum AFP levels in patients suffering from 47 different types of cancers and noncancer diseases. Progress Molecular Biol Transl Sci 162:199–212
Bao L, Zhao J, Dai X, Wang Y, Ma R, Su Y, Cui H, Niu J, Bai S, Xiao Z et al (2014) Correlation between miR-23a and onset of hepatocellular carcinoma. Clin Res Hepatal Gastroenterol 38:318–330